Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Oncological Medicine
Volume 2013, Article ID 154674, 5 pages
Case Report

Intrathecal Trastuzumab Treatment of the Neoplastic Meningitis due to Breast Cancer: A Case Report and Review of the Literature

1 Department of Medical Oncology, Jules Bordet Institute, Boulevard de Waterloo, 121, 1000 Brussels, Belgium
2Supportive Care Unit, Jules Bordet Institute, Boulevard de Waterloo, 121, 1000 Brussels, Belgium

Received 26 November 2012; Accepted 30 December 2012

Academic Editors: P. F. Lenehan, R. Martinez, and R. Yamamoto

Copyright © 2013 Cristina Dumitrescu and Dominique Lossignol. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


We report the case of a 65-year-old woman, diagnosed with a breast cancer human epidermal growth factor receptor (HER2) previously negative, who developed leptomeningeal carcinomatosis and was treated with intrathecal (IT) trastuzumab (TST). After five doses of IT trastuzumab, at escalading doses, once weekly, the patient's neurological status stabilised, and that result was maintained for two months. There is evidence in the literature that breast cancer receptor status may change over time, and when it occurs, it may modify the therapeutical approach. We reviewed the pertinent literature and concluded that IT trastuzumab might be a promising treatment for patients with HER2-positive breast cancer leptomeningeal carcinomatosis.